NCT05672537招募中2 期
Duvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk, Phase II, Single Center, Randomized Controlled Study
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2023年1月20日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- 1-year relapse free survival rate
研究概览
简要总结
This study is a randomized controlled study to evaluate the efficacy and safety of Durvalumab combined with GemCis for neoadjuvant treatment of high recurrence risk ICC
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age ≥ 18, male or female;
- •Pathological diagnosis confirmed intrahepatic cholangiocarcinoma, which could be resected surgically; One of the following conditions shall be met:
- •2.1 Single tumor, diameter greater than 5cm (T1b) 2.2 Single tumor with vascular invasion (T2), multiple tumors ≤ 3 2.3 Tumor penetrating visceral peritoneum (T3) or directly invading surrounding organs (T4) 2.4 Suspicious lymph node metastasis in Zone 8, 12 or 13
- •Can not received systemic treatment before participating in the study;
- •ECOG PS score 0-1;
- •The main organs function normally, and there is no serious blood, heart, lung, liver, kidney, bone marrow and other functional abnormalities and immune deficiency diseases.
- •Laboratory inspection shall meet the following requirements:
- •Women of childbearing age must have a negative pregnancy test (serum or urine) within 14 days before enrollment, and voluntarily use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of the study drug; For men, they should be surgically sterilized or agree to use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of the study drug.
- •The patient voluntarily participated and signed the informed consent form;
- •It is expected that the compliance is good, and the efficacy and adverse reactions can be followed up according to the requirements of the scheme.
排除标准
- •Patients who received PD-1, PD-L1, PD-L2, CTLA-4 before enrollment, or directly received another stimulatory or co inhibitory T cell receptor (such as CTLA-4, 0X40, CD137);
- •Any other research drugs within 4 weeks before enrollment;
- •Any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism after hormone replacement therapy);
- •Congenital or acquired immune function defects, such as human immunodeficiency virus (HIV) infection;
- •Uncontrollable clinical cardiac symptoms or diseases, such as NYHA II and above heart failure unstable angina pectoris, myocardial infarction within one year, and clinically significant supraventricular or ventricular arrhythmia requiring clinical intervention;
- •Severe infection (such as intravenous drip of antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first drug administration, or fever of unknown cause>38.5 ° C occurred during screening/before the first drug administration;
- •History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- •Live attenuated vaccine shall be inoculated within 4 weeks before the first administration or planned during the study period;
- •Suffered from or accompanied by other system malignant tumors in the last 5 years (except cured skin basal cell carcinoma, cervical carcinoma in situ and ovarian cancer);
- •Allergic to any test drug;
- •Pregnant and lactating women, fertile subjects are unwilling to take effective contraceptive measures;
- •Uncontrollable psychosis;
- •Other situations that the researcher thinks are not suitable for inclusion. If the patient has central nervous system metastasis, has serious laboratory examination abnormalities, and is accompanied by family or social factors, it will affect the safety of the subject, or the collection of data and samples.
研究组 & 干预措施
Durvalumab Combined with GemCis Neoadjuvant Therapy Group
Experimental
干预措施: Gemcitabine (Drug)
Durvalumab Combined with GemCis Neoadjuvant Therapy Group
Experimental
干预措施: Durvalumab (Drug)
Durvalumab Combined with GemCis Neoadjuvant Therapy Group
Experimental
干预措施: Cisplatin (Drug)
Surgical treatment group
Experimental
干预措施: Surgery (Procedure)
结局指标
主要结局
1-year relapse free survival rate
时间窗: 1-year
次要结局
- Occurrence of adverse reactions(1-year)
- ORR(1-year)
- DCR(1-year)
- 2-year relapse free survival rate(2-year)
- 30 day postoperative complication rate(30 day)
- 2-year OS(2-year)
- R0 resection rate(1-year)
- 1-year OS(1-year)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)Non-small Cell Lung CancerNCT05925530AstraZeneca142
终止
2 期
Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for CisplatinMuscle-invasive Bladder CancerNCT03234153Insel Gruppe AG, University Hospital Bern6
尚未招募
2 期
Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical StudyIb-IIIb NSCLCNCT04897386Wuhan Union Hospital, China30
撤回
2 期
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic CholangiocarcinomaBorderline Resectable CarcinomaBiliary Tract CancerNCT06017297Georgetown University28
终止
2 期
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast CancerHormone Receptor Positive TumorBreast CancerNCT03874325H. Lee Moffitt Cancer Center and Research Institute17